Cue Biopharma, Inc. / Fundamentals
Income statement
- Net revenue
€7.11M - Cost of goods sold
€85.80K - Gross profit
€7.02M - SG&A expenses
€12.64M - R&D expenses
€28.25M - EBITDA
-€31.33M - D&A
€1.39M - EBIT
-€33.79M - Interest expenses
€441.01K - EBT
-€33.37M - Tax expenses
€0.00 - Net income
-€33.37M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€3.17M - Changes in working capital
-€1.86M - Operating cash flow
-€24.15M - Capex
€152.72K - Other investing cash flow
€84.08K - Net investing cash flow
-€68.64K - Total cash dividends paid
€0.00 - Issuance of common stock
€24.81M - Debt repayment
-€1.72M - Other financing cash flow
€14.43M - Net financing cash flow
€22.04M - Foreign exchange effects
€0.00 - Net change in cash
-€2.05M - Cash at end of period
€23.72M - Free cash flow
-€23.99M
Balance sheet
- Cash and cash equivalents
€23.59M - Cash and short-term investments
€23.59M - Total receivables
€456.46K - Inventory
€0.00 - Other current assets
€2.42M - Total current assets
€26.46M - Property, plant & equipment
€4.78M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€3.68M - Total non-current assets
€8.46M - Total assets
€34.93M - Accounts payable
€3.11M - Short-term debt
€3.89M - Other current liabilities
€9.52M - Total current liabilities
€16.52M - Long-term debt
€2.66M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€163.02K - Total non-current liabilities
€2.83M - Total liabilities
€19.35M - Common stock
€65.21K - Retained earnings
-€311.11M - Other equity
€0.00 - Total equity
€15.58M - Total liabilities and shareholders' equity
€34.93M
Company information
- Market capitalization
€47.62M - Employees
41 - Enterprise Value
€42.14M
Company ratios
- Gross margin
-
98.8% Even with peer group: 96.7% - EBITDA margin
-
-440.7% Much better than peer group: -13,543.8% - EBIT margin
-
-475.2% Much better than peer group: -13,661.7% - EBT margin
-
-469.3% Much better than peer group: -13,261.2% - Net margin
-
-469.3% Much better than peer group: -13,453.3% - ROE
-
-214.2% Much worse than peer group: -89.6% - ROA
-
-95.5% Worse than peer group: -76.9% - Asset turnover
-
20.4% Much worse than peer group: 88.1% - FCF margin
-
-341.7% Much better than peer group: -14,780.4% - FCF yield
-51.0% - Efficiency ratio
540.7% - Net sales per employee
-
€173.42K - Net income per employee
-
-€813.95K